Randomized phase II study of the combination of oral vinorelbine with capecitabine versus gemcitabine in combination with paclitaxel versus gemcitabine in combination with docetaxel as first line chemotherapy in patients with metastatic breast cancer [Studio randomizzato di fase II sull'utilizzo in prima linea della combinazione vinorelbine orale e capecitabina verso le combinazioni gemcitabina e paclitaxel e gemcitabina e docetaxel in pazienti con carcinoma mammario metastatico]

Trial Profile

Randomized phase II study of the combination of oral vinorelbine with capecitabine versus gemcitabine in combination with paclitaxel versus gemcitabine in combination with docetaxel as first line chemotherapy in patients with metastatic breast cancer [Studio randomizzato di fase II sull'utilizzo in prima linea della combinazione vinorelbine orale e capecitabina verso le combinazioni gemcitabina e paclitaxel e gemcitabina e docetaxel in pazienti con carcinoma mammario metastatico]

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Aug 2014

At a glance

  • Drugs Vinorelbine (Primary) ; Capecitabine; Docetaxel; Gemcitabine; Paclitaxel
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms NORCAP
  • Most Recent Events

    • 16 Aug 2014 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database record.
    • 30 May 2014 Primary endpoint 'Disease-control-rate' has been met.
    • 30 May 2014 Final results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top